Medically reviewed by Drugs.com. Last updated on May 25, 2020.
(e REN ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution Auto-injector, Subcutaneous [preservative free]:
Aimovig: erenumab-aooe 70 mg/mL (1 mL); erenumab-aooe 140 mg/mL (1 mL) [contains polysorbate 80]
Aimovig (140 MG Dose): erenumab-aooe 70 mg/mL (1 mL [DSC]) [contains polysorbate 80]
Brand Names: U.S.
- Aimovig (140 MG Dose) [DSC]
- Antimigraine Agent
- Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
- Monoclonal Antibody, CGRP Antagonist
Erenumab is a human monoclonal antibody that antagonizes calcitonin gene-related peptide (CGRP) receptor function.
Vz: 3.86 L
Via a nonspecific, nonsaturable proteolytic pathway
Time to Peak
Use: Labeled Indications
Migraine prophylaxis: Preventive treatment of migraine in adults
Serious hypersensitivity to erenumab or any component of the formulation.
Migraine prophylaxis: SubQ: Initial: 70 mg once a month; some patients may benefit from 140 mg once a month
Missed dose: Administer missed dose as soon as possible, and schedule next dose for 1 month from date of the last dose.
Refer to adult dosing.
SubQ: For subcutaneous use only; intended for self-administration. Keep out of direct sunlight and allow to come to room temperature for 30 minutes before administration. Do not warm using a heat source (eg, hot water, microwave) and do not shake. Administer in abdomen (avoiding 2 inches around the navel), thigh or upper arm, avoiding areas of skin that are tender, bruised, red or hard. Deliver entire contents of single-use autoinjector or prefilled syringe.
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light until time of use. If removed from the refrigerator, should be kept at room temperature (up to 25°C [77°F]) in the original carton and used within 7 days. Do not freeze or shake.
There are no known significant interactions.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%:
Gastrointestinal: Constipation (3%; with serious complications)
Immunologic: Antibody development (3% to 6%; neutralizing: <1%)
Local: Injection site reaction (5% to 6%)
Neuromuscular & skeletal: Muscle cramps (≤2%), muscle spasm (≤2%)
Frequency not defined:
Dermatologic: Injection site pruritus
Local: Erythema at injection site, pain at injection site
Cardiovascular: Exacerbation of hypertension, hypertension
Dermatologic: Skin rash
Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction
Concerns related to adverse effects:
• Constipation: Constipation, including cases with serious complications resulting in hospitalization and surgery, has been reported. Constipation has generally occurred after the first dose; however, a later onset has also been observed. Concurrent use of medications that decrease GI motility may increase the risk for more severe constipation and the potential for constipation-related complications.
• Hypersensitivity: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported. Most reactions are mild to moderate and occur within hours after administration, but some may be delayed for >1 week. If a hypersensitivity reaction occurs, discontinue treatment and institute appropriate therapy.
• Hypertension: New-onset and worsening of preexisting hypertension, including cases requiring pharmacological treatment or hospitalization, have been reported. Onset most frequently reported after the initial dose and within 7 days of administration but may occur at any time. Monitor patients and consider discontinuing treatment in patients whom an alternative etiology is not established.
Disease related concerns:
• Cardiovascular disease: May cause hypertension; use with caution in patients with hypertension or risk factors for hypertension.
Dosage form specific issues:
• Latex: The packaging (needle shield of auto-injector and needle cap of prefilled syringe) may contain latex.
Number of monthly migraine days; BP.
Adverse events were not observed in animal reproduction studies.
What is this drug used for?
• It is used to prevent migraine headaches.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Injection site redness, swelling, or pain
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Severe headache
• Passing out
• Vision changes
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
- Emgality vs Aimovig - how do they compare?
- Ajovy vs Aimovig: What's the difference between them?
- How long does it take for Aimovig to start working?
- Does Aimovig cause weight gain or loss?
- Why does Aimovig cause constipation?
- What is the mechanism of action of Aimovig?
More about erenumab
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- En Español
- 550 Reviews
- Drug class: CGRP inhibitors
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.